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The U.S. Environmental ProtectionAgencyis underacongressional mandate to revise its current
standard for arsenic in drinking water. We present a risk assessment for cancers ofthe bladder,
liver, and lung from exposure to arsenic in water, based on data from 42 villages in an arseniasis-
endemicregion ofTaiwan. We calculate excess lifetime riskestimates for several variations ofthe
generalizedlinearmodel andforthemultistage-Weibull model. Riskestimates are sensitveto the
model choice, towhether or not acomparison population is used to definethe unexposed diease
mortalityrates, and towhether the comparison population is all ofTaiwan orjustthe southwest-
em region. Some factors that mayaffect risk could not be evaluated quantitativel. the ecologic
nature of the data, the nutritional status of the study population, and the dietary intake of
arsenic. Despite all ofthese sources ofuncertainty, however, ouranalysis suggests that the current
standard of50 pg/L is asoatted with asubstantial increased riskofcancer and is not sufficiently
protective of public health. Key wordr bladder cancer, generalized linear model, lifetime
death risk, lung cancer, margin of exposure, multistage-Weibull. Environ Health Perspect
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A metal found in rocks and mineral forma-
tions in the earth's crust, arsenic has long
been associated with the development ofcan-
cer in humans. Exposure can occur via
inhalation, primarily in industrial settings, or
through ingestion. Because drinking water is
one ofthe primary routes of exposure, stan-
dards set in 1942 established a maximum
contaminant level (MCL) of 50 pg/L in
drinking water. In 1975, 50 pg/L was adopt-
ed as the interim standard in response to the
1974 Safe DrinkingWaterAct (1). In a 1984
health assessment, the U.S. Environmental
Protection Agency (EPA) dassified arsenic as
a dass A human carcinogen, based primarily
on epidemiologic evidence, and produced
quantitative risk estimates for both ingestion
and inhalation routes of exposure (2).
Although the EPA assessment for the inhala-
tion route is well accepted, the risk assess-
ment for ingestion remains controversial.
The 1984 risk assessment for arsenic in
drinking water was based on an epidemio-
logic study in Taiwan that examined an
association between arsenic exposure via
drinking water and skin cancer (non-
melanoma) (3). EPA investigators estimated
that the lifetime risk ofskin cancer for indi-
viduals who consumed 2 L water per day at
50psg/L could be as high as 2 in 1,000. This
high value prompted questions about the
1984 risk assessment, including applicability
of the risk assessment to the U.S. popula-
tion, the role ofarsenic as an essential nutri-
ent, the relevance ofskin lesions as the basis
for the risk assessment, and the role of
arsenic intake via food. In 1988, the EPA
Risk Assessment Forum published a revised
skin cancer risk assessment and focused
attention on these questions (4). The EPA is
currently under a congressional mandate to
finalize a new rule for arsenic in drinking
water by 1 January 2001 (5).
There has been substantial focus on the
association between arsenic and skin cancer,
and there is also substantial evidence that
exposure to arsenic in drinking water increas-
es the mortality risk for several internal can-
cers. Increases in bladder and lung cancer
mortality were found in a region ofnorthern
Chile (6). An association was also found
between bladder cancer mortality and
arsenic in drinking water in Argentina (7).
Significant increased mortality was observed
for males and females in Taiwan due to lung,
liver, skin, kidney, and bladder cancer (8).
The National Research Council presents a
more detailed summary ofthe evidence link-
ing arsenic exposure to internal cancer (1).
The purpose ofthis article is to present a
risk assessment for mortality due to several
internal cancers based on a reanalysis of the
data reported by Chen et al. (8). Brown (9)
discussed the limitations ofthe data available
for analysis when the current EPA risk
assessment (4) was prepared. For several rea-
sons, it can be argued that the risk assess-
ment of internal cancers presented in this
paper yields more convincing results than
the previous EPA assessment based on skin
cancer. First, the current study focuses on
mortality from bladder, lung, and liver can-
cers identified through national death
records. In addition, unlike the Tseng et al.
(3) study that was used in the EPA analysis,
which grouped data into three broad
exposure intervals [low (< 300 pg/L), medi-
um (300-600 pg/L), and high (> 600
pg/L)], data now available provide exposure
at the individual village level.
This paper is a follow-up to a prelimi-
nary study that focused only on bladder
cancer and examined model sensitivity
(10). The current analysis is expanded to
include lung and liver cancers and examines
issues of dose-response modeling by
Poisson regression, in addition to applica-
tion of the multistage-Weibull (MSW)
model, in more detail.
Materials and Methods
Internal cancer data. Data used in this
analysis were derived from a study in an arse-
niasis-endemic area of Taiwan (11-13).
Cancer mortality data were collected from
death certificates of residents of 42 villages
during 1973-1986. These datawere original-
ly collected in 1987, so only records up to
1986 were available. Causes of death were
classified according to the Eighth Revision of
International Classification ofDiseases, 1965
Revision (ICD) (14). The data consisted of
person-years at risk and the number ofdeaths
due to bladder (ICD code 188), lung (ICD
code 162), and liver (ICD code 155) cancer
in 5-year age increments for both males and
females. Table 1 summarizes the internal
cancer data and provides person-years at risk
and observed number of cancer deaths by
age, sex, and arsenic level. Although individ-
ual village arsenic levels are available and will
be used in subsequent analyses, exposure lev-
els are grouped in Table 1 for convenience of
presentation. The numbers of bladder, liver,
and lung cancers are given, along with the
number ofperson-years at risk. For example,
males between the ages of 50 and 69 con-
tributed 21,040 person-years at risk and 6,
17, and 12 deaths were observed from blad-
der, liver, and lungcancer, respectively.
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Exposure data. Drinking water samples
were collected from wells of 42 villages in
1964-1966 (12). The artesian wells were
gradually closed; the last one dosed in mid-
1970. Although mortality data were collect-
ed for a later time period (1973-1986), it is
likely that arsenic levels in well water
remained relatively unchanged over this time
period. It could also be argued that because
ofthe long latency ofthe cancers ofinterest,
it is appropriate for exposure to be based on
a time period 10 to 20 years before death. A
strength of the currently available exposure
data is that individual well concentration
levels are available for each village. Physical
and chemical characteristics of drinking
water such as pH value and levels ofarsenic,
sodium, calcium, magnesium, manganese,
iron, mercury, chromium, lead, nitrite and
nitrate nitrogen, fluoride, and bicarbonate
have been intensively studied in both
Blackfoot disease-endemic and -nonendemic
areas (15,16). Arsenic level was the only level
that was significantly higher than the maxi-
mal allowable limit and strikingly different
in water from shallow wells and artesian
wells. The data also have some limitations.
The drinking water was not tested for levels
of dissolved radon and other a-emitters.
Fluorescent compounds, especially humic
acids, have been found in the well water.
These fluorescent substances result from the
decomposition oforganic matter, particular-
ly dead plants. However, it is unlikely that
their presence causes confounding in this
analysis becausewidespread contamination is
not confined to the arseniais-endemic area.
Standardized mortality ratio. We used
standardized mortality ratios (SMRs) to sum-
marize the observed patterns of mortality in
data. SMRs provide a popular approach to
comparing mortality in a specific population
with mortality from a suitable comparison
population (17). SMRs correspond to ratios
of observed and expected number of events
and are calculated by10/XEi, where 0, is
the observed number ofdeaths in the ih age
group and Ei is the corresponding expected
number ofdeaths, calculated by multiplying
the study population size (P,) by the age-spe-
cific cancer death rate (M) in a comparison
population (i.e., Ei = P.xM). Usually SMRs
are expressed as a percentage so that the value
100 x 12Oil/Ei is the number reported.
There are concerns with using all ofTaiwan
as a comparison population because of the
potential for bias associated with differences
in the populations (e.g., rural vs. urban). For
this reason, we considered two comparison
populations in this analysis: all of Taiwan
and the southwestern region ofTaiwan (18).
The latter is expected to provide a more suit-
able comparison basis for the study popula-
tion, which is largely rural and fairly poor.
Table 2 contains the data from the two com-
parison populations. The number of deaths
due to bladder, lung, and liver cancers and
person years at risk (PYR) were extracted by
agegroup and sex for 1973-1986.
Generalizedlinear model, Poisson mod-
eling is often used in epidemiologic analysis,
particularly for rare events such as cancer
deaths. In fact, SMRs can correspond to
maximum likelihood estimates of risk ratios
from a Poisson model (17). In our analysis,
we assumed that the number of deaths due
to cancer follows a Poisson distribution with
parameter equal to the person-years at risk
multiplied by the hazard ofdying ofcancer.
The hazard is often modeled as a function of
age (t) and exposure (x). As described by
Breslow and Day (17), a broad class ofmod-
els can be characterized using the following
general form,
h(x,t) = ho(t) Xg(x), [1]
where h0(4 denotes the baseline hazard func-
tion that only depends on age, t, and
describes the instantaneous hazard ofdyingof
cancer for the unexposed population. The risk
ratio attributed to exposure level xis denoted
byg(x). Ofcourse, it is likely that a variety of
factors, including cigarette smoking, use of
bottled water, and dietary intake ofinorganic
arsenic, could influence or even confound the
model. The model described in Equation 1
will allow consideration of other covariates.
Unfortunately, measurements for these and
other potentially important factors were not
available for our study. Rather, this is an eco-
logic study wherein only relatively simple
exposure and population characteristics could
be measured. It will be important to consider
this and other sources of uncertainty when
interpreting the results. Although not dis-
cussed extensively here, it is possible for the
risk ratio g(x) to also depend on age, t. For
example, older people may be more suscepti-
ble to exposure. We did in fact explore such
age-dependent risk models and found that in
general, it was adequate to model the relative
risk as a function of exposure only. A wide
range of models was obtained by varying a)
the use ofcomparison populations; b) theway
age is modeled in ho(4, e.g., linear, quadratic,
or the use ofregression splines; c) transforma-
tions ofexposure concentrations; and a) the
wayexposure is modeled. Table 3 summarizes
the various modeling options considered in
this analysis. Each model corresponds to
choosing one option from each column. For
example, the model excluding the comparison
population, with a linear age effect, an expo-
nential linear dose effect, and no transforma-
tion on dose, is characterized by ho(t) =
exp(ao + clt) and g(x) = exp(,lx). Note that
the linear and quadratic dose-effect models
(generally referred to as additive models) do
not fit into the usual dassofgeneralizedlinear
models (GLMs) and require special program-
ming. Exponential linear and exponential
quadratic models fall under the general dass
ofmultiplicative models. The spline age effect
was modeled using natural splines because of
the ease of obtaining predicted values (19).
There are three options for the baseline haz-
ard: model the hazard without including a
comparison population, treat the comparison
population as an unexposed group, or replace
the baseline hazard function with empirical
Table 1. Person-years at risk by age, sex, and arsenic level with observed number of deaths from cancer
(bladder, liver, and lung).
Sex, arsenic Age (years)a
level (pg/I) 20-30 30-49 50-69 >70 Total
Male
< 100 35,818 34,196 21,040 4,401 95,455
(0,0,0) (1,10,2) (6,17,12) (10,4,14) (17,31,28)
100-299 18,578 16,301 10,223 2,166 47,268
(0,0,0) (0, 4, 3) (7, 15,14) (2,4,13) (9, 23,30)
300-599 27,556 25,544 15,747 3,221 72,068
(0,3,0) (5,7, 9) (15, 23, 30) (12, 6,14) (32, 39, 53)
. 600 16,609 15,773 8,573 1,224 42,179
(0,0, 1) (4, 12,3) (15, 15, 23) (8,2,6) (27, 29, 33)
Total 98,561 91,814 55,583 11,012 256,970
(0, 3, 1) (10, 33, 17) (43, 70, 79) (32, 16, 47) (85, 122, 144)
Female
< 100 27,901 32,471 21,556 5,047 86,975
(0, 0, 0) (3,1, 5) (9, 6,18) (9, 5, 5) (21, 12,29)
100-299 13,381 15,514 11,357 2,960 43,212
(0, 0,0) (0, 3, 4) (9, 6,10) (2,5, 5) (11, 14,19)
300-599 19,831 24,343 16,881 3,848 64,903
(0, 0, 0) (0, 5, 6) (19, 6,20) (11, 2,10) (30,13, 36)
.600 12,988 15,540 9,084 1,257 38,869
(0, 0, 0) (0, 4, 6) (21, 7, 28) (7, 1,4) (28, 12, 38)
Total 74,101 87,868 58,878 13,112 233,959
(0, 0, 1) (3, 13, 21) (58, 25, 76) (29, 13, 24) (90, 51, 122)
"Values in parentheses are number of deaths from bladder, liver, and lung cancer, respectively.
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estimates based on the comparison popula-
tion (not included in Table 1). The third
option can be accomplished by fitting a
Poisson model containing indicators corre-
sponding to the age categories observed in the
comparison population. This approach essen-
tially corresponds to the traditional SMR
approach. Because there were no villages with
zero concentration levels, the method used to
model the baseline hazard had a fairly strong
influence on the results. In particular, the
choice of whether to include a comparison
population had a strong influence. The use of
an unexposed comparison population has the
potential to provide more information about
the shape ofthe model at low concentrations.
Although not a member of the usual
GLM class, the MSW model was also
considered because it was used in the previ-
ous risk assessment (4). The MSW corre-
sponds to letting g(x) = PO + IX + 2x2 and
ho(t) = C(t- To)+ (10), where tdenotes age
and x denotes exposure concentration. The
plus sign (+) indicates a truncation on the (t
- To) term (i.e., if To > tthen the term is set
to zero). Results based on the MSW model
are only presented for comparison. The
GLM approach has several advantages over
the MSW model. First, the MSW model
appears to be more sensitive to outliers than
the GLM model (1J). Also, the hazard func-
tion for the MSW model involves a trunca-
tion in tthat complicates estimation. Finally,
the inclusion of the power parameter k (for
our purposes, k = 2) tends to give the fitted
model a relatively sublinear shape that leads,
Table 2. Comparison population data, 1973-1986.
Sex, All-Taiwan Southwestern region
age Deaths(n) Deaths(n)
(years) PYR Bladder Lung Liver PYR Bladder Lung Liver
Male
20-25 13,271,386 3 45 206 2,956,638 2 14 43
25-30 11,054,191 4 86 426 2,175,046 3 26 88
30-35 8,628,516 8 144 782 1,580,019 2 33 140
35-40 6,793,545 20 217 1,351 1,320,637 6 38 245
40-45 6,375,466 50 447 2,030 1,327,866 18 89 403
45-50 6,384,052 91 951 3,145 1,334,769 34 181 565
50-55 6,062,515 164 1,852 4,140 1,214,443 52 323 716
55-60 5,018,542 213 2,882 4,562 977,820 61 478 832
60-65 3,666,535 345 3,557 4,030 739,460 103 595 722
65-70 2,443,367 413 3,569 3,259 520,965 126 607 704
70-75 1,480,126 418 2,658 2,107 320,158 130 465 463
75-80 720,375 305 1,318 1,170 158,750 88 230 246
80-85 287,294 146 512 436 63,236 32 80 103
85+ 105,411 66 152 188 22,651 15 22 33
Female
20-25 12,612,276 0 39 81 2,595,529 0 7 15
25-30 10,548,089 2 70 134 1,846,189 2 19 34
30-35 8,210,507 2 102 168 1,402,764 0 17 39
35-40 6,458,620 5 205 247 1,215,899 2 41 53
40-45 5,802,856 20 365 396 1,191,615 8 75 75
45-50 5,157,821 41 525 590 1,111,810 14 112 138
50-55 4,335,755 76 730 763 957,985 36 160 169
55-60 3,517,193 124 1,018 1,018 774,836 52 200 255
60-65 2,776,622 153 1,224 1,039 634,758 77 258 243
65-70 2,106,715 173 1,280 1,039 492,203 68 230 235
70-75 1,490,659 185 1,062 875 342,767 70 190 199
75-80 888,468 157 707 602 199,630 43 108 127
80-85 433,245 81 330 300 96,293 21 45 59
85+ 217,590 41 136 153 46,089 9 10 31
PYR, person-years. Data from the Department of Health (18).
Table 3. Poisson modeling options.
Comparison population Age effecthoat) Dose transformation Dose effect g(x)
None Linear Linear Linear
exp(aO + x X, x=ppba PJx
Southwestern Taiwan Quadratic Logarithmic Quadratic
exp(ot, +act+ 2f2) x=log(l +ppb) l1Xx+l32
All ofTaiwan Regression spline Square root Exponential linear
exp[xo+(xins(4lb x=ppb exp(,lx)
Exponential quadratic
exp(p1x+02xk2)
&Represents exposure concentration in parts per billion, which is equivalent to micrograms per liter. bns~ft represents a
natural spline applied to t.
in general, to higher benchmark doses than
the GLM models.
Quantitative riskassessment. Because the
risk ofdying from cancer is age dependent, it
is common to base risk assessment on the
excess risk of dying from cancer over the
course ofa typical lifetime. The adjusted life-
time death risk can be calculated by integrat-
ing the death hazard over the typical lifetime
in the population ofinterest,
Idr(x) =f1oh(xt)S(t)dt,
where S(t) is the probability of surviving
until age tand h(x,t) is the hazard for dying
ofthe cancer ofinterest at age tfor someone
exposed at level x. Applying integration by
parts, Idr(x) can also be written as
Idr(x) = 1-JO,k(t)S(t)dt,
where X(t) denotes the hazard ofdying at age
tfrom causes other than the cancer ofinter-
est. This function can be approximated by
ldr(x) 7,1 Sq,exp[-5Ih(x,s)j
t S<t
where Idenotes the sum over all 5-year age
groups in the study and qt is the probability
ofdyingduring the 5-year time interval indi-
cated by t. Values for qtwere taken from the
1996 U.S. population lifetable for males and
females (Table 4) (20).
Traditionally, standards for carcinogenic
compounds have been set by finding the
exposure level that yields a rate of 10- over
background. As suggested by Brown (9) and
discussed by Smith and Sharp (21), this esti-
mate is probably unreliable for epidemiolog-
ic data, where exposure is not typically mea-
sured accurately enough to extrapolate to
such low risk levels. The new EPAguidelines
for cancer risk assessments (22) suggest the
use of a point-of-departure analysis for set-
tings where the mode ofaction is supportive
oflinearity or there is insufficient support for
a nonlinear mode of action. The idea is to
Table 4. U.S. death probabilities by age and sex,
1996.
Probability of death (q)
Age (years) Male Female
20-25 0.00742 0.00239
25-30 0.00755 0.00307
30-35 0.00962 0.00423
35-40 0.01227 0.00595
40-45 0.01621 0.00834
45-50 0.02182 0.01224
50-55 0.03144 0.01938
55-60 0.04622 0.02938
60-65 0.06966 0.04577
65-70 0.09278 0.06417
70-75 0.12183 0.09207
75-80 0.14149 0.12267
80-85 0.15457 0.16036
85+ 0.24949 0.41813
Data from VitalStatistics ofthe United States, 1996120).
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estimate a point on the exposure response
curve within the observed range of the data
and then extrapolate linearly to lower doses.
The dose associated with 10% excess risk
(EDIO) is the standard point ofdeparture, but
often in epidemiologic studies, an excess risk
of 10% is fairly large and occurs only at rela-
tively high doses. We will use both 1% and
5% excess risks for the point of departure
(EDO0 andED05, respectively). Wecomputed
confidence intervals for excess lifetime risk
using the Delta method (23). Bootstrap
methods were also used for models with non-
parametric age effects, yielding similar results
(24). The new guidelines also suggest a mar-
gin-of-exposure analysis (MOE), defined as
the point of departure divided by the
environmental exposure of interest. This
approach is the proposed default mode of
action when linearity is not the most reason-
able assumption (22). For subsequent discus-
sion we will use MOE01(50) to represent the
margin ofexposure using the EDO1 point of
departure and 50 1ig/L as the environmental
exposureofinterest.
Results
Table 5 contains adescriptive summary ofthe
internal cancer data, showing person-years at
risk, observed number of cancers, and the
SMRs for age, sex, and exposure grouped
into the same intervals used by the EPA in
the skin cancer risk assessment. As in Wu et
al. (12), the analysis is limited to persons
. 20 years of age because there were essen-
tially no cancer deaths observed in those
younger than 20 years ofage. Note that the
entire Taiwanese population was used to cal-
culate the expected deaths used in the com-
putation ofSMRs in Table 5. Although the
computed SMRs display a large amount of
noise, there appear to be higher SMRs at
high exposure levels compared to exposures
in the lower range, especially for bladder and
lung cancer. There is no observed tendency
in SMRs with respect to age, which suggests
no age dependency on the risk ratio, g(x),
defined in Equation 1. Overall, females have
higher SMRs than males. Liver cancer mor-
tality is generally higher than expected,
although there is no particularly strong
exposure-response relationship.
The GLM analysis began by fitting all
possible models and comparing the Akaike
information criterion (AIC) to narrow the
model choice (25). The AIC is a commonly
used criterion for comparing nonnested
models. It penalizes the model deviance by
Table 5. Summary statistics.
Observed no. of cancer deaths (SMRa x 100)
Villages (n) PYRb Bladder Lung Liver Combined
Overall 42 490,929 175 (1,327) 266 (266) 173 (134) 614 (254)
Exposure (pg/L)
0-50 8 92,920 26 (1,002) 30 (156) 29 (118) 85 (183)
50-100 6 102,797 12 (415) 31 (143) 18 (65) 61 (116)
100-200 4 40,679 12(1,047) 21 (243) 19 (174) 52 (251)
20-300 3 36,514 8 (766) 24 (308) 14 (144) 46 (247)
300-400 4 28,870 6 (744) 12 (197) 6 (77) 24 (163)
400-500 3 28,655 22 (2,968) 21 (365) 12 (160) 55 (393)
500-600 7 79,446 34 (1,490) 56 (332) 34 (159) 124 (306)
600+ 7 81,048 55 (3,271) 71 (514) 41 (217) 167 (486)
Age (years)
20-40 42 258,789 2 (1,446) 5 (178) 18 (169) 25 (184)
40-60 42 164,549 21 (730) 116 (365) 76 (130) 213 (228)
60+ 42 67,591 121 (1,189) 145 (222) 79 (133) 345 (256)
Sex
Male 42 256,970 85 (1,005) 144 (220) 122 (127) 351 (206)
Female 42 233,959 90 (1,904) 122 (354) 51 (158) 263 (368)
&Definition from Breslow and Day (17).b1973.1986.
adding twice the number ofparameters to it.
Thus a model with a low AIC will be one
that describes the observed data well (a low
deviance) yet with relatively few parameters
(small penalty). The models with the lowest
AIC provide the best fit. Because it was not
appropriate to compare AIC for the models
based on different data sets, we provide sepa-
rate analyses with and without comparison
populations.
Table 6 identifies models 1-9 and the
MSWmodel that appear in Tables 7-10 and
Figures 1-3. For simplicity we will refer to
the model numbers. Table 7 compares the
four top performing models based on AMC
for the models with and without comparison
populations for male bladder cancer. Several
other models fit reasonably well, but we
chose to present only four (see "Discussion").
It is important to note, however, that models
indudingexposure concentration were highly
significant compared to models excluding
-concentration. We also present the MSW
model. Although detailed results are shown
here only for male bladder cancer, the same
general patterns apply to females and to all
cancer outcomes except for the combined
analysis (see "Discussion"). In general, mod-
els with no transformation on dose and an
exponential linear dose effect fit well when
we used no comparison population. When
we used population data from the southwest-
ern region ofTaiwan or the entire Taiwanese
population, models with the square root and
log transformation fit well. This is most likely
Table 6. Model description.
Model
1
2
3
4
5
6
7
8
9
MSW
Dose
transformation
Identity
Identity
Identity
Log
Log
Log
Sqrt
Sqrt
Sqrt
Identity
Dose
effecta
Linear
linear
Quadratic
Linear
Quadratic
Quadratic
Linear
Quadratic
Quadratic
Quadratic
Age
effect
Quadratic
Spline
Spline
Quadratic
Quadratic
Spline
Quadratic
Quadratic
Spline
Truncated
aExponential linear or exponential quadratic.
0.10
.m 0.08
L..
a 0.08
0.04
0 500 1,000 1,5W 2000
U.S.equivalentconcentration(igl/L)
Figure 1. Estimated lifetime death risk for male
bladder cancer without comparison population.
For a description of models, see Table 6.
0W o 500 1,000 1,500 2,000 U.S. equivalentconcentration(jg/L)
U.S.equuivalent concentration (jig/I) Figure 3. Estimated lifetime death risk for male
Figure2. Estimated lifetime death riskfor male blad- bladder cancer with southwestern Taiwanese
der cancer with Taiwanese-wide comparison pop- region comparison population. For a description
ulation. For a description ofmodels, see Table 6. of models, see Table 6.
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due to the relatively low cancer death rates in
the comparison population. The log-transfor-
mation allowed the fitted curve to rise more
quickly from zero to accommodate this dif-
ference. Using the log-transformation with-
out the comparison population gave a good
model fit, according to AIC, but risk esti-
mates were not easy to interpret because of
instability of the fitted model at low dose.
For this reason, we chose not to pursue the
log-transformation without the comparison
population any further. A few additive mod-
els gave a good fit, but in most cases, the
multiplicative models did a better job, so we
chose not to continue with the additive mod-
els. Also note that the MSW model fit rea-
sonably well (Figures 1-3 show graphical
representations). Each dot in Figures 1-3
corresponds to the estimated lifetime risk of
dying ofbladder cancer for villages, grouped
by 50-pg/L exposure levels (0-50, 50-100,
etc.). The grouping is for presentation pur-
poses only because village-specific estimates
were highly variable. The idea of grouping
for the purpose ofgraphical presentation ofa
fitted model has been widely used in the
logistic regression context as well (26). Fitted
curves for the models without the compari-
son population are very similar in shape,
whereas there is a considerable amount of
variability in the models with a comparison
population.
Tables 8-10 contain riskstatistics for the
best-fitting GLM models and the MSW
model with andwithout comparison popula-
tion data. Concentrations are reported in
U.S. equivalent concentrations of arsenic in
drinking water, based on conversions that
account for the average weight and average
water intake for a male living in the United
States compared to a male living in Taiwan.
For models 1 and 2, which have no transfor-
mation on dose, EDOI estimates equal 395
and 351 pg/L, respectively, for male bladder
cancer. For models 3, 4, and 5, which have a
log-transformed dose effect, EDO0 estimates
for male bladder cancer range from 21 to 54
pg/L. Models 7 and 8, which have a square
root dose effect, give higher estimates (156
and 108 pg/L, respectively). Results for
model 9 are similar to models 7 and 8. When
Table 7. AIC for best-fitting models.
All of Southwestern
Model None Taiwan area
1 302.1655
2 302.5547
3 334.8289 326.9948
4 302.9700 326.6287
5 330.0863
6 303.3353 330.9968
7 326.1207
8 327.1098
9 333.8307
a comparison population is used (Tables 9 Estimates ofED and ED05 based on using
and 10), there is more variability in the pre- the southwestern region ofTaiwan tended to
dicted lifetime risk from model to model. It be much lower than those based on using
appears that the inclusion of a large unex- the Taiwanese-wide population. The MSW
posed comparison population had a relative- model implies a lower riskwhen no compar-
ly strong influence on estimation of risk. ison population was used (ED01 = 633 pg/L
Table8. Concentrations (pg/I) for different measures of risk (without comparison population).
Bladder Lung Liver Combined
Model no." M F M F M F M F
lb
ED01 395 252 364 258 573 673 169 121
LED01 326 211 294 213 437 410 148 105
MOE01(50) 7.9 5.0 7.3 5.2 11.5 13.5 3.4 2.4
ED05 1,277 813 1,345 885 -c - 720 493
LEDo5 1,076 690 1,086 733 - - 629 430
MOE05(50) 25.54 16.3 26.9 17.7 - - 14.4 9.9
2d
ED01 351 244 343 256 585 657 164 120
LED01 296 209 279 215 451 405 144 106
MOE01(50) 7.0 4.9 6.9 5.1 11.7 13.1 3.3 2.4
ED05 1,181 796 1,288 879 - - 703 492
LED05 1,005 683 1,045 735 - - 617 433
MOE05(50) 23.6 15.9 25.8 17.6 - - 14.1 9.8
Mswe
ED01 633 365 227 396 864 824 163 267
MOE01(50) 12.7 7.3 4.5 7.9 17.3 16.5 3.3 5.3
ED05 1,439 828 1,171 898 - - 706 605
MOE05(50) 28.8 16.6 23.4 18.0 - - 14.1 12.1
aDosetransformation, dose effect, and age effect, respectively. bidentity, linear, and quadratic.CED,5 outside the observ-
able range ofdata. 'Identity, linear, and spline. 'Identity, quadratic, and truncated.
Table9. Concentrations (pg/L) for different measures of risk (with Taiwanese comparison population).
Bladder Lung Liver Combined
Model no.a M F M F M F M F
3b
ED01 22 21 11 8 254 331 3 2
LED01 18 17 8 6 54 63 3 2
MOE01(50) 0.4 0.4 0.2 0.2 5.1 6.6 0.1 0.0
ED05 504 330 1,145 448 -C - 111 54
LED05 355 248 514 260 - - 76 42
MOE05(50) 10.1 6.6 22.9 9.0 - - 2.2 1.1
5d
ED01 23 19 11 8 239 339 3 2
LED01 19 16 8 6 51 65 3 2
MOE01(50) 0.5 0.4 0.2 0.2 4.8 6.8 0.1 0.0
ED05 539 304 1,276 476 - - 113 56
LED05 380 231 564 274 - - 77 43
MOE05(50) 10.8 6.1 25.5 9.5 - - 2.3 1.1
6e
ED01 41 17 128 33 608 404 86 9
LED01 18 9 42 10 337 87 35 3
MOE01(50) 0.8 0.3 2.6 0.7 12.2 8.1 1.7 0.2
ED05 611 293 925 491 - - 389 125
LED05 416 185 684 346 - - 278 75
MOE05(50) 12.2 5.9 18.5 9.8 - - 7.8 2.5
9f
ED01 100 72 76 68 895 511 45 17
LED01 65 52 32 34 542 148 19 10
MOE01(50) 2.0 1.4 1.5 1.4 17.9 10.2 0.9 0.3
ED05 708 407 978 579 - - 499 228
LED 516 309 659 433 - - 337 160
MOj5(50) 14.2 8.1 19.6 11.6 - - 10.0 4.6
MSwg
ED01 164 88 196 116 480 551 106 53
MOE01(50) 3.3 1.8 3.9 2.3 9.6 11.0 2.1 1.1
ED05 852 455 1,014 579 1,089 - 544 273
MOE 5(50) 17.0 9.1 20.3 11.6 21.8 - 10.9 5.5
Dose transformation, dose effect, and age effect, respectively. hLog, linear, and quadratic.cED,5 outside the observable
range of data. "Log, linear, and spline. "log, quadratic, and spline. fSqrt, quadratic, and spline. #Identity, quadratic, and
truncated.
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Table 10. Concentrations (pg/L) for different measures of risk (southwestern Taiwanese comparison pop-
ulation).
Bladder Lung Liver Combined
Model no.8 M F M F M F M F
4b
ED01 21 19 10 10 119 467 3 2
LED01 17 16 8 8 37 76 2 2
MOE01(50) 0.4 0.4 0.2 0.2 2.4 9.3 0.1 0.0
ED05 649 452 768 522 -c - 93 63
LED05 422 313 403 312 - - 66 48
MOE05(50) 13.0 9.0 15.4 10.4 - - 1.9 1.3
5d
ED01 54 25 76 27 503 455 62 9
LED01 21 12 22 9 247 110 22 3
MOE01(50) 1.1 0.5 1.5 0.5 10.1 9.1 1.2 0.2
ED05 723 464 780 520 - - 330 132
LED05 508 315 558 362 _ _ 226 79
MOE05(50) 14.5 9.3 15.6 10.4 - - 6.6 2.6
7e
ED01 156 136 79 76 309 485 21 20
LED01 131 117 62 63 174 242 17 17
MOE01(50) 3.1 2.7 1.6 1.5 6.2 9.7 0.4 0.4
ED05 917 624 880 608 - - 347 250
LED05 786 548 705 510 - - 292 219
MOE05(50) 18.3 12.5 17.6 12.2 - - 6.9 5.0
8f
ED01 108 85 50 63 779 559 31 18
LED01 65 56 25 35 400 168 14 10
MOE01(50) 2.2 1.7 1 1.3 15.6 11.2 0.6 0.4
ED05 817 536 778 582 - - 416 238
LED05 594 406 489 431 - - 275 167
MOE05(50) 16.3 10.7 15.6 11.6 - - 8.3 4.8
MSW
EDoa 185 101 181 113 709 597 98 55
M8E01(50) 3.7 2.0 3.6 2.3 14.2 11.9 2.0 1.1
ED05 959 520 936 583 1,608 - 506 284
M0E05(50) 19.2 10.4 18.7 11.7 32.2 - 10.1 5.7
Dose transformation, dose effect, and age effect, respectively. bLog, linear, and quadratic.CED01 outside the observable
range of data. dLog, quadratic, and quadratic. eSqrt, linear, and quadratic. 'Sqrt, quadratic, and quadratic.
for male bladder cancer) compared to esti-
mates when a comparison population is used
(164 and 185 jig/L).
Discussion
In contrast to the 1988 EPA risk assessment
that focused on skin cancer incidence (4),
this studyexamines cancer mortality in a set-
ting where exposure is measured at village
level. Although there is an advantage to hav-
ing individual village measurements, there
also appears to be variability in the exposure
assessment, causing high variability in the
risk estimates. Depending on the model and
whether or not a comparison population is
used in the analysis, EDO1 estimates range in
value from 21 to 633 jig/L for male bladder
cancer. For males, the lung cancer risk tends
to be slightly higher than the risk for bladder
cancer, withEDOI values ranging from 10 to
364 pg/L. Although this result seems in con-
trast to the high SMRs for bladder cancer in
Table 5, the risk estimates are calculated on
an additive scale and are influenced by back-
ground cancer rates. Hence, even though
bladder cancer has high SMRs, the number
of excess bladder cancer deaths associated
with exposure is only moderate because of
the low bladder cancer death rate in the gen-
eral population. In contrast, because lung
cancer is more prevalent in the general pop-
ulation, even a moderate SMR can lead to
high numbers of excess deaths. There does
not appear to be high risk associated with
liver cancer in males with the exception of
estimates based on three models that used a
log-transformation ofexposure (models 3, 4,
and 5). EDOI estimates range from 309 to
895 pg/L for models apart from the latter,
which yields values that range from 199 to
254 pg/L. The risk associated with female
cancers tends to be higher than that ofmales
for each cancer type. For bladder cancer,
EDOI estimates for females range from 17 to
365 gg/L. For lung and liver cancer, female
EDOI estimates range from 8 to 396 pg/L
and 331 to 824 gg/L, respectively. The best
models according to AIC for bladder, lung,
and liver cancer combined did not exactly
correspond to the models presented in
Tables 8-10. For males, the best model with
no comparison population is model 1, which
has a linear untransformed dose effect and a
quadratic age effect (Table 8). For females
the best model for combined cancer has a
square root transformation on dose with a
quadratic dose and age effect. The EDO1 esti-
mate based on this model equals 844 pg/L.
When a comparison population is used
(either all of Taiwan or the southwestern
region of Taiwan), the best model for both
males and females has a square root transfor-
mation on dose with a linear dose effect and
spline age effect. EDOI estimates based on this
model with the entire Taiwanese population
equal 22 and 18 pg/L for males and females,
respectively. When the southwestern region
was used, EDOI estimates equal 21 and 20
pg/L for males and females, respectively.
Our results show that exposure-response
assessments depend highly on the choice of
model, as well as whether or not a compari-
son population is used in the analysis. As dis-
cussed by Morales et al. (10), one possible
explanation is the uncertainty associated
with an ecologic study design. We assumed
the same arsenic concentration for all per-
sons in the same village and individual expo-
sures can vary widely in a village. Mortality
records are available for individuals, but their
individual exposures are not. The National
Academy ofSciences (1) provides a good dis-
cussion on this subject.
Although one might argue that the
appropriate strategy would be to select the
best model based on accepted statistical cri-
teria, several models gave essentially the same
quality fit (as measured by AIC), yet yielded
substantial differences in risk estimates. For
example, for the models without a compari-
son population, the MSW model gave a fit
comparable to some of the GLM models,
but producedEDOI estimates almost twice as
high. Despite the comparably good fit, we
preferred the GLM models to the MSW
model. For example, sensitivity analysis
revealed that the MSW model was influ-
enced strongly by the removal of various
subsets ofvillages, whereas the GLM was not
(10). The poor nutritional status of the
Taiwanese in the Blackfoot disease region
could be another contributing factor of
uncertainty. We could not account for
dietary intake of inorganic arsenic in food
for either population, or for other con-
founders in this analysis.
Differences in EDOI estimates were par-
ticularly affected by whether or not a com-
parison population was used. There is reason
to believe that the urban Taiwanese popula-
tion is not a comparable population for the
poor rural population used in this study.
Thus, risk estimates using the Taiwanese
population may be biased. As an alternative,
we used the southwestern region ofTaiwan;
we found very different risk estimates based
on the two different comparison populations
(Tables 9 and 10). We could havedone other
analyses. For example, we could have calculat-
ed lifetime death rates for the unexposed
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group [Idr(0)] using U.S. population data. It
would be of interest to see how the unex-
posed death rates in the United States com-
pare to the death rates in Taiwan.
Despite the considerable variation in
estimated EDO0, the results are sobering and
indicate that current standards are not ade-
quately protective against cancer. For the
combined analysis with no comparison pop-
ulation and identity transformation on dose,
the MOE01(50) values range from 0.4 to
16.9 for both males and females. When we
include a comparison population, the
MOE01(50) values range from 0.2 to 3.4.
The current arsenic standard of 50 j.g/L (4)
is actually below the estimated EDO0, which
suggests that the risk at the current standard
is higher than 1 in 100. Note, however, this
estimate is likely to be overly conservative
because the data suggest that the log-trans-
formations lead to somewhat unstable
results. Even considering the identity trans-
formation, which tended to give less extreme
results, the risk associated with a concentra-
tion of 50 pg/L is approximately 1 in 300,
based on linear extrapolation from the point
of departure. Risks of a similar magnitude
were reported by Smith et al. (27). This is an
extremely high value. We could argue that if
indeed the risk were this high, we would
expect to find epidemiologic evidence even
within the U.S. population. The SEER
Cancer Statistics Review (28) estimates that
the age-adjusted U.S. mortality rates for
bladder, lung, and liver cancer are 3.2, 49.5,
and 2.8 per 100,000, respectively. It is also
estimated that approximately 5% of large
and small regulated water supply systems in
the United States have arsenic concentra-
tions > 20 )ig/L (291). Thus, ifthe excess can-
cer risk associated with 50 pg/L arsenic is on
the order of magnitude 1 in 1,000, we
would expect an increase of approximately
0.05 per 1,000 or 5 per 100,000 in the pop-
ulation. It is not surprising that epidemio-
logic studies in the United States have not so
far been able to identify clear associations.
Thus, we conclude that arsenic in drinking
water may indeed be contributing to excess
cancer mortality in the United States.
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